Dishman Carbogen Amcis' Q1FY27 performance saw net revenue dip 4.3% YoY to ₹677.64 Cr, largely due to deferred CDMO projects.

The company reported a net loss of ₹57.88 Cr, compared to a ₹23.41 Cr profit last year.

EBITDA plunged 57.3% to ₹60.08 Cr, with margins shrinking to 8.9%. CDMO revenue dropped 12.6% YoY to ₹534.38 Cr, as customers rescheduled about CHF 10 million worth of projects to the second half of FY27. However, the Marketable Molecules segment shined, growing 48% YoY to ₹143.26 Cr, boosted by Cholesterol sales.

Strategically, Dishman is focusing on boosting capacity utilization, diversifying client base, and expanding its ADC & Bioconjugation services.

Oncology remains a key area, with 12 molecules in late-stage development.

While CDMO margins were hit by fixed costs and a ₹11.73 Cr forex loss, Marketable Molecules margins are stable with full-year FY26 trends, and management expects deferred projects to boost H2FY27 results.